DPEP-1 Potential and Arch New Mechanism of Action Currently, no specific therapies exist to prevent AKI in the world today. Management of AKI is supportive and includes life-sustaining therapy with dialysis. Patients that experience AKI are at high risk of developing chronic kidney disease, adverse cardiovascular outcomes and death.The worldwide market for AKI is estimated to be over $20 billion USD per year. ($325.4 dollars a share). As we wait for Human Data and are hoping for a signal of any kind from this new mechanism of action,.I am thinking of a question that was posed to the Chief Science Officer in the last webinar and the wealth that would be created by being an industry leader in this space.
Q) Does Arch have other drugs that target DPEP-1?
A) "The answer is yes, we have been working on this pathway for several years and while LSALT was the lead candidate we have developed a number of other molicules that also target the DPEP pathway. This includes a varariety of novel peptides that have been modified to improve thier pharmacologic properties, we are also developing antibodies that can target DPEP-1. We also have method of use patents on existing small molecules that block the enzymatic activility of DPEP-1. We will be advancing 2 of the small molecules into preclinical pipeline in the next month or two. These 2 molicules are not ready for human clinical studies yet and they still need to undergo the pre clincal testing before advancing into human studies, but we will be advancing a few of our products hopefully before the end of the year"
35:00 Min Mark